Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Nepetin

$524

  • Brand : BIOFRON

  • Catalogue Number : BD-P0605

  • Specification : 95.0%(HPLC)

  • CAS number : 520-11-6

  • Formula : C16H12O7

  • Molecular Weight : 316.3

  • PUBCHEM ID : 5317284

  • Volume : 10mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0605

Analysis Method

Specification

95.0%(HPLC)

Storage

-20℃

Molecular Weight

316.3

Appearance

Powder

Botanical Source

This product is isolated and purified from the flower of Chrysanthemum zawadskii var. latilobum

Structure Type

Category

SMILES

COC1=C(C2=C(C=C1O)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O

Synonyms

5,7,3',4'-Tetrahydroxy-6-methoxyflavone/Flavone, 3',4',5,7-tetrahydroxy-6-methoxy-/Nepetin/4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxy-/2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxychromen-4-one/3',4',5,7-Tetrahydroxy-6-methoxyflavone/6-METHOXYLUTEOLIN/Eupafolin/2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-6-methoxy-4H-chromen-4-one

IUPAC Name

Applications

Density

1.6±0.1 g/cm3

Solubility

Methanol; DMF

Flash Point

250.9±25.0 °C

Boiling Point

659.1±55.0 °C at 760 mmHg

Melting Point

267ºC

InChl

InChl Key

FHHSEFRSDKWJKJ-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:520-11-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

24289155

Abstract

Background & aim
Due to known limitations of liver biopsy, reliable non-invasive serum biomarkers for chronic liver diseases are needed. We performed serum peptidomics for such investigation in compensated chronic hepatitis B (CHB) patients.

Methods
Liquid chromatography combined with tandem mass spectrometry (LC-MS/MS) was used to identify differentially expressed peptides in sera from 40 CHB patients (20 with S0G0-S1G1 and 20 with S3G3-S4G4). Ion pair quantification from differentially expressed peptides in a validation set of sera from 86 CHB patients was done with multiple reaction monitoring (MRM).

Results
21 differentially represented peptide peaks were found through LC-MS/MS. Ion pairs generated from eleven of these peptides (m/z < 800) were quantified by MRM. Summed peak area ratios of 6 ion pairs from peptide m/z 520.3 (176.1, 353.7, 459.8, 503.3, 351.3, 593.1), which was identified as dihydroxyacetone kinase (DAK) fragment, decreased from mild to advanced stages of fibrosis or inflammation. Area Under Receiver Operating Characteristic Curves (AUROCs) of five ion models discriminating fibrosis degrees were 0.871 ~ 0.915 (S2-4 versus S0-1) and 0.804 ~ 0.924 (S3-4 versus S0-2). AUROCs discriminating inflammation grades were 0.840 ~ 0.902 (G2-4 versus G0-1) and 0.787 ~ 0.888 (G3-4 versus G0-2). The diagnostic power of these models provides improved sensitivity and specificity for predicting disease progression as compared to aspartate aminotransferase to platelet ratio index (APRI), FIB-4, Forn’s index and serum DAK protein. Conclusions The peptide fragment (m/z 520.3) of DAK is a promising biomarker to guide timing of antiviral treatment and to avoid liver biopsy in compensated CHB patients.

KEYWORDS

Peptidome, Dihydroxyacetone kinase, Chronic hepatitis B, Multiple reaction monitoring, Liquid chromatography combined with tandem mass spectrometry

Title

Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B

Author

Ming-Yi Xu,#1 Xiao-Fang Jia,#2 Ying Qu,1 Rui-Dan Zheng,3 Zheng-Hong Yuan,2 Hong-Lei Weng,4 Steven Dooley,4 Xing-Peng Wang,1 Li-Jun Zhang,corresponding author2 and Lun-Gen Lucorresponding author1

Publish date

2013;

PMID

30029854

Abstract

Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) viruses. We isolated mAbs from human survivors of ebolavirus disease and identified a potent mAb, EBOV-520, which bound to an epitope in the glycoprotein (GP) base region. EBOV-520 efficiently neutralized EBOV, BDBV, and SUDV and also showed protective capacity in relevant animal models of these infections. EBOV-520 mediated protection principally by direct virus neutralization and exhibited multifunctional properties. This study identified a potent naturally occurring mAb and defined key features of the human antibody response that may contribute to broad protection. This multifunctional mAb and related clones are promising candidates for development as broadly protective pan-ebolavirus therapeutic molecules.

KEYWORDS

ebolavirus, monoclonal antibodies, viral antibodies, neutralizing antibodies, cross protection, heterologous immunity, glycoproteins, Ebola hemorrhagic fever, epitopes, epitope mapping

Title

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein

Author

Pavlo Gilchuk,1 Natalia Kuzmina,6,7 Philipp A. Ilinykh,6,7 Kai Huang,6,7 Bronwyn M. Gunn,9 Aubrey Bryan,10 Edgar Davidson,10 Benjamin J. Doranz,10 Hannah L. Turner,11 Marnie L. Fusco,13 Matthew S. Bramble,14,15 Nicole A. Hoff,14 Elad Binshtein,4 Nurgun Kose,1 Andrew I. Flyak,2 Robin Flinko,16 Chiara Orlandi,16 Robert Carnahan,1 Erica H. Parrish,1 Alexander M. Sevy,3 Robin G. Bombardi,1 Prashant K. Singh,4 Patrick Mukadi,17 Jean Jacques Muyembe-Tamfum,17 Melanie D. Ohi,4,18 Erica Ollmann Saphire,11,12,13 George K. Lewis,16 Galit Alter,9 Andrew B. Ward,11 Anne W. Rimoin,14 Alexander Bukreyev,6,7,8,18,∗ and James E. Crowe, Jr.1,2,3,5,18,19,∗∗

Publish date

2018 Aug 21;

PMID

24960209

Abstract

We have developed a series of dihydroxy compounds and related analogues based on our hybrid D2/D3 agonist molecular template to develop multifunctional drugs for symptomatic and neuroprotective treatment for Parkinson’s disease (PD). The lead compound (−)-24b (D-520) exhibited high agonist potency at D2/D3 receptors and produced efficacious activity in the animal models for PD. The data from thioflavin T (ThT) assay and from transmission electron microscopy (TEM) analysis demonstrate that D-520 is able to modulate aggregation of alpha-synuclein (αSN). Additionally, coincubation of D-520 with αSN is able to reduce toxicity of preformed aggregates of αSN compared to control αSN alone. Finally, in a neuroprotection study with dopaminergic MN9D cells, D-520 clearly demonstrated the effect of neuroprotection from toxicity of 6-hydroxydopamine. Thus, compound D-520 possesses properties characteristic of multifunctionality conducive to symptomatic and neuroprotective treatment of PD.

KEYWORDS

Parkinson’s disease, D2/D3 agonist, alpha-synuclein, neuroprotection, multifunctional drug

Title

Multifunctional D2/D3 Agonist D-520 with High in Vivo Efficacy: Modulator of Toxicity of Alpha-Synuclein Aggregates

Author

Gyan Modi,† Chandrashekhar Voshavar,† Sanjib Gogoi,† Mrudang Shah,† Tamara Antonio,‡ Maarten E. A. Reith,‡§ and Aloke K. Duttacorresponding author†*

Publish date

2014 Aug 20